Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients

Autor: Marjon Elfferich, Marjolein Drent, Aalt Bast, Naomi T Jessurun, Petal A. Wijnen, V. L. J. Proesmans
Přispěvatelé: Faculteit FHML Centraal, MUMC+: DA CDL Analytisch cluster 1K (9), Farmacologie en Toxicologie, RS: FSE UCV Adaptive responses in relation to health effect and safety of nutrition, RS: NUTRIM - R3 - Respiratory & Age-related Health, RS: CARIM - R2.03 - ECM + Wnt signaling, RS: Carim - H03 ECM and Wnt signaling
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Male
Indoles
Time Factors
Gastrointestinal Diseases
Gastroenterology
DISEASE
Antifibrotic drugs
chemistry.chemical_compound
Idiopathic pulmonary fibrosis
0302 clinical medicine
Risk Factors
Weight loss
030212 general & internal medicine
Side effects
Netherlands
media_common
Aged
80 and over
PIRFENIDONE
Pirfenidone
Middle Aged
Treatment Outcome
SAFETY
Vomiting
Female
Nintedanib
medicine.symptom
medicine.drug
Adult
Pulmonary and Respiratory Medicine
medicine.medical_specialty
Pyridones
Nausea
media_common.quotation_subject
DIAGNOSIS
Risk Assessment
Interstitial Lung Disease
03 medical and health sciences
Internal medicine
medicine
MANAGEMENT
Humans
Adverse effect
Aged
business.industry
Appetite
medicine.disease
Treatment
Cross-Sectional Studies
IPF
030228 respiratory system
chemistry
CLINICAL-PRACTICE
Health Care Surveys
Self Report
business
Zdroj: Lung, 197(5), 551-558. Springer, Cham
Lung
ISSN: 0341-2040
Popis: Purpose Idiopathic pulmonary fibrosis (IPF) is an inexorably progressive disease, which has a great impact on patients' lives. Pirfenidone and nintedanib are approved and recommended antifibrotic drugs for patients with IPF. The aim of this study was to evaluate self-reported gastrointestinal side effects of antifibrotic drugs in 176 Dutch IPF patients. Methods A cross-sectional web-based anonymous survey about complaints and side effects was conducted among IPF patients in the Netherlands. Logistic regression was used to quantify whether pirfenidone and nintedanib caused complaints of nausea, vomiting, diarrhoea, appetite loss, weight loss or loss of taste or smell perception. Results The questionnaire was completed by 176 IPF patients, 71 of whom used pirfenidone and 85 nintedanib, while 20 patients did not use any antifibrotic drugs. Nintedanib users reported complaints of diarrhoea, vomiting, weight loss and loss of appetite (p
Databáze: OpenAIRE
Externí odkaz: